Matinas BioPharma Holdings, Inc. SEC filings MTNB
Matinas BioPharma Holdings, Inc. has 570 filings in SEC EDGAR's recent list, going back to Jul 25, 2013. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 425 | Filing | Aug 25, 2026 | — |
| 425 | Filing | Aug 4, 2026 | — |
| 425 | Filing | Jul 30, 2026 | — |
| 425 | Filing | Jul 29, 2026 | — |
| 425 | Filing | Jul 21, 2026 | — |
| 425 | Filing | Jul 16, 2026 | — |
| 425 | Filing | Jul 13, 2026 | — |
| EFFECT | Filing | Apr 29, 2025 | — |
| CORRESP | Letter to the SEC | Apr 28, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 28, 2025 | — |
| NT 10-K | Filing | Mar 31, 2025 | Dec 31, 2024 |
| D | Filing | Feb 19, 2025 | — |
| EFFECT | Filing | Jun 20, 2023 | — |
| CORRESP | Letter to the SEC | Jun 16, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2023 | — |
| DEL AM | Filing | Jun 15, 2023 | — |
| EFFECT | Filing | Aug 7, 2020 | — |
| CORRESP | Letter to the SEC | Jul 31, 2020 | — |
| CORRESP | Letter to the SEC | Jul 27, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 24, 2019 | — |
| PRER14A | Filing | Sep 23, 2019 | — |
| CORRESP | Letter to the SEC | Sep 23, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 20, 2019 | — |
| EFFECT | Filing | Apr 12, 2017 | — |
| CERTNYS | Auto-generated paper document | Mar 1, 2017 | — |
| 8-A12B | Filing | Mar 1, 2017 | — |
| D | Filing | Jan 26, 2017 | — |
| SC TO-I/A | Filing | Jan 19, 2017 | — |
| SC TO-I/A | Filing | Jan 5, 2017 | — |
| CORRESP | Letter to the SEC | Dec 28, 2016 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2016 | — |
| SC TO-I | Filing | Dec 14, 2016 | — |
| EFFECT | Filing | Nov 18, 2016 | — |
| CORRESP | Letter to the SEC | Nov 16, 2016 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2016 | — |
| CORRESP | Letter to the SEC | Sep 20, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 19, 2016 | — |
| D | Filing | Aug 12, 2016 | — |
| EFFECT | Filing | Apr 27, 2016 | — |
| EFFECT | Filing | Jul 23, 2015 | — |
| CORRESP | Letter to the SEC | Jul 21, 2015 | — |
| CORRESP | Letter to the SEC | Jul 8, 2015 | — |
| UPLOAD | Letter from the SEC | Jun 17, 2015 | — |
| EFFECT | Filing | May 7, 2015 | — |
| CORRESP | Letter to the SEC | May 5, 2015 | — |
| UPLOAD | Letter from the SEC | May 1, 2015 | — |
| CT ORDER | Filing | May 1, 2015 | — |
| D | Filing | Apr 13, 2015 | — |
| EFFECT | Filing | May 21, 2014 | — |
| SP 15D2 | Special financial report | Apr 11, 2014 | Dec 31, 2013 |
| EFFECT | Filing | Feb 12, 2014 | — |
| CORRESP | Letter to the SEC | Feb 11, 2014 | — |
| UPLOAD | Letter from the SEC | Jan 31, 2014 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2014 | — |
| DRS/A | Filing | Dec 20, 2013 | — |
| UPLOAD | Letter from the SEC | Nov 1, 2013 | — |
| DRS | Filing | Oct 4, 2013 | — |
| D | Filing | Aug 7, 2013 | — |
| D | Filing | Jul 25, 2013 | — |
Showing 61 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MTNB (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bedminster, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1582554
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.